Show simple item record

dc.contributor.authorCores, Ángel
dc.contributor.authorAbril, Sheila
dc.contributor.authorMichalska, Patrycja
dc.contributor.authorDuarte, Pablo
dc.contributor.authorOlives, Ana I.
dc.contributor.authorMartín, M. Antonia
dc.contributor.authorVillacampa, Mercedes
dc.contributor.authorLeón, Rafael
dc.contributor.authorCarlos Menéndez, J.
dc.contributor.otherUAM. Departamento de Farmacologíaes_ES
dc.date.accessioned2022-01-04T12:36:17Z
dc.date.available2022-01-04T12:36:17Z
dc.date.issued2021-06-10
dc.identifier.citationAntioxidants 10.6 (2021): 941en_US
dc.identifier.issn2076-3921es_ES
dc.identifier.urihttp://hdl.handle.net/10486/699539
dc.description.abstractOxidative stress is crucial to the outbreak and advancement of neurodegenerative diseases and is a common factor to many of them. We describe the synthesis of a library of derivatives of the 4-arylmethylen-2-pyrrolin-5-one framework by sequential application of a three-component reaction of primary amines, β-dicarbonyl compounds, and α-haloketones and a Knoevenagel condensation. These compounds can be viewed as cyclic amides of caffeic and ferulic acids, and are also structurally related to the bisavenanthramide family of natural antioxidants. Most members of the library showed low cytotoxicity and good activity as inductors of Nrf2, a transcription factor that acts as the master regulator of the antioxidant response associated with activation of the antioxidant response element (ARE). Nrf2-dependent protein expression was also proved by the significant increase in the levels of the HMOX1 and NQO1 proteins. Some compounds exerted neuroprotective properties in oxidative stress situations, such as rotenone/oligomycin-induced toxicity, and also against protein hyperphosphorylation induced by the phosphatase inhibitor okadaic acid. Compound 3i, which can be considered a good candidate for further hit-to-lead development against neurodegenerative diseases due to its well-balanced multitarget profile, was further characterized by proving its ability to reduce phosphorylated Tau levelsen_US
dc.description.sponsorshipThis research was funded by the Spanish ministry of Science, Innovation and Education (grant RTI2018-097662-B-I00 to J.C.M.), IS Carlos III co-financed by the European Regional Development funds (FEDER) (grants PI17/01700 and PI20/00433 to R.L.) and Comunidad Autónoma de Madrid (grants B2017/BMD-3813, J.C.M., and B2017/BMD-3827, R.L.). The APC were not fundeden_US
dc.format.extent22 pag.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.ispartofAntioxidantsen_US
dc.rights© 2021 by the authorsen_US
dc.subject.otherBisavenanthramidesen_US
dc.subject.otherKeap1en_US
dc.subject.otherNeurodegenerative diseasesen_US
dc.subject.otherNrf2 regulationen_US
dc.subject.otherNrf2–ARE pathwayen_US
dc.subject.otherOxidative stressen_US
dc.titleBisavenathramide analogues as Nrf2 inductors and neuroprotectors in in vitro models of oxidative stress and hyperphosphorylationen_US
dc.typearticleen_US
dc.subject.ecienciaFarmaciaes_ES
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/antiox10060941es_ES
dc.identifier.doi10.3390/antiox10060941es_ES
dc.identifier.publicationfirstpage941-1es_ES
dc.identifier.publicationissue6es_ES
dc.identifier.publicationlastpage941-22es_ES
dc.identifier.publicationvolume10es_ES
dc.relation.projectIDGobierno de España. RTI2018-097662-B-I00es_ES
dc.relation.projectIDGobierno de España. PI17/01700es_ES
dc.relation.projectIDGobierno de España. PI20/00433es_ES
dc.relation.projectIDComunidad de Madrid. B2017/BMD-3827/NRF24AD-CMes_ES
dc.relation.projectIDComunidad de Madrid. B2017/BMD-3813/ELA-MADRID-CMes_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccesses_ES
dc.authorUAMAbril Comesaña, Sheila (271157)
dc.authorUAMMichalska Dziama, Patrycja (271205)
dc.authorUAMDuarte Flórez, Pablo (281295)
dc.authorUAMLeón Martínez, Rafael (264118)
dc.facultadUAMFacultad de Medicina
dc.institutoUAMInstituto Teófilo Hernando de I+D del Medicamento (ITH)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record